Domestic vaccine maker Medigen Vaccine Biologics Corp’s (高端疫苗) shot has already been used by President Tsai Ing-wen (蔡英文) over better-known, more established inoculations.
Now the company is aiming to sell 100 million doses next year by gaining clearance from three to five additional countries, Medigen chief executive officer Charles Chen (陳燦堅) said in an interview.
The ambitious target comes even as Medigen has not yet started the final trials typically required for approval. About 660,000 doses have been given locally thus far based on early study results.
Photo: Sam Yeh, AFP
The company, which is developing vaccines for dengue fever and hand, foot and mouth disease, is targeting neighboring countries in Asia and Taiwan’s 15 diplomatic allies, mainly nations in Latin America, the Caribbean and the Pacific, as potential purchasers, he said.
“You must focus on the countries that believe in your medical quality,” Chen said in Taipei on Friday. “There are certain countries that believe that any clinical data, government endorsement from Taiwan is reliable. Those are the countries that we focus on.”
Medigen joined an elite group of fewer than two dozen companies, including industry behemoths Pfizer Inc and AstraZeneca PLC, when it won authorization to sell its shot in Taiwan last month.
It will have to overcome numerous hurdles, including its price, to meet its lofty sales target. Chief among them will be persuading health authorities overseas to approve an immunization from a little-known company with sparse data and no track record of bringing immunizations to market.
Shares of Medigen have risen 169 percent this year, compared to the 17 percent gain of the Taipei Exchange Index, where it is listed.
The company has a lot of competition, with nearly 100 rival vaccines in development. More than a dozen have started the third and final phase of study needed to reach the market.
Medigen plans to start its phase 3 trial, a head-to-head comparison with AstraZeneca’s vaccine in Paraguay, later this month with 1,000 participants. That compares with other companies that plan to enroll thousands more in their pivotal trials, as well as the initial studies, which typically have a higher bar, that included 30,000 or more volunteers each.
It might be challenging to enroll enough participants to persuade regulatory authorities outside of Taiwan, said Mia He, an analyst with Bloomberg Intelligence who tracks the industry.
Vaccinations are already being offered in many places and rival clinical trials have recruited many of those willing to participate, she said.
Chen said he hopes data from the company’s studies that show the vaccine’s effect on the immune system compared to proven shots will be sufficient to win international backing.
He acknowledged that securing approval from US or European drug regulators might be crucial to the company’s chances of selling its COVID-19 shots overseas.
Pricing is another issue. The government placed an order for 5 million doses with an option for 5 million more at a price of up to NT$880 (US$31.8) per dose, according to a report by Taipei-based Mirror Media. That makes it among the most expensive vaccines.
Although prices vary widely, estimates are that Moderna Inc’s vaccine costs at least US$31, whereas AstraZeneca is typically the cheapest, coming in at about US$5 per dose after the company pledged to sell at cost.
Chen said the price per dose would come down as Medigen ramps up production.
The rollout of Medigen’s vaccine is a boost for Taiwan amid a struggle to secure shots from overseas.
Although its outbreaks have been small compared with most other places, Taiwan has fallen behind when it comes to vaccination. Only about 4 percent of the population was fully vaccinated as of Sunday, one of the lowest rates among developed economies.
Almost 45 percent of people have had one dose.
RUN IT BACK: A succesful first project working with hyperscalers to design chips encouraged MediaTek to start a second project, aiming to hit stride in 2028 MediaTek Inc (聯發科), the world’s biggest smartphone chip supplier, yesterday said it is engaging a second hyperscaler to help design artificial intelligence (AI) accelerators used in data centers following a similar project expected to generate revenue streams soon. The first AI accelerator project is to bring in US$1 billion revenue next year and several billion US dollars more in 2027, MediaTek chief executive officer Rick Tsai (蔡力行) told a virtual investor conference yesterday. The second AI accelerator project is expected to contribute to revenue beginning in 2028, Tsai said. MediaTek yesterday raised its revenue forecast for the global AI accelerator used
TEMPORARY TRUCE: China has made concessions to ease rare earth trade controls, among others, while Washington holds fire on a 100% tariff on all Chinese goods China is effectively suspending implementation of additional export controls on rare earth metals and terminating investigations targeting US companies in the semiconductor supply chain, the White House announced. The White House on Saturday issued a fact sheet outlining some details of the trade pact agreed to earlier in the week by US President Donald Trump and Chinese President Xi Jinping (習近平) that aimed to ease tensions between the world’s two largest economies. Under the deal, China is to issue general licenses valid for exports of rare earths, gallium, germanium, antimony and graphite “for the benefit of US end users and their suppliers
Dutch chipmaker Nexperia BV’s China unit yesterday said that it had established sufficient inventories of finished goods and works-in-progress, and that its supply chain remained secure and stable after its parent halted wafer supplies. The Dutch company suspended supplies of wafers to its Chinese assembly plant a week ago, calling it “a direct consequence of the local management’s recent failure to comply with the agreed contractual payment terms,” Reuters reported on Friday last week. Its China unit called Nexperia’s suspension “unilateral” and “extremely irresponsible,” adding that the Dutch parent’s claim about contractual payment was “misleading and highly deceptive,” according to a statement
Artificial intelligence (AI) giant Nvidia Corp’s most advanced chips would be reserved for US companies and kept out of China and other countries, US President Donald Trump said. During an interview that aired on Sunday on CBS’ 60 Minutes program and in comments to reporters aboard Air Force One, Trump said only US customers should have access to the top-end Blackwell chips offered by Nvidia, the world’s most valuable company by market capitalization. “The most advanced, we will not let anybody have them other than the United States,” he told CBS, echoing remarks made earlier to reporters as he returned to Washington
RSS